More Articles

MSF launches online ‘Patent Opposition Database’ Policies & Legislation | Posted 26/10/2012

The international medical humanitarian organisation Doctors Without Borders/Médecins Sans Frontières (MSF) has launched an online resource to help civil society and patient groups in developin...

Future biosimilar targets Reports | Posted 26/10/2012

It seems biological medicines are set to play a major part in the pharmaceutical industry’s future and they already play a major part in its current growth [1]. At the moment, biologicals account f...

Glossary of key terms Biosimilars/General | Posted 26/10/2012

Last update: 13 February 2015Confusion may sometimes surround terms used in the fields of generics and biosimilars. This has been recognized as a problem by EMA, who has expressed the need to...

Reliance Life Sciences starts ‘similar’ infliximab trial in India Biosimilars/News | Posted 26/10/2012

Reliance Life Sciences is starting a clinical trial for a ‘similar biologic’ version of infliximab in patients suffering with rheumatoid arthritis in India.

Mylan sues FDA over Ranbaxy’s generic Diovan exclusivity Generics/News | Posted 26/10/2012

US-based Mylan has sued FDA for refusing to grant approval to sell a generic version of Novartis’s heart treatment, Diovan HCT (valsartan/hydrochlorothiazide), ‘after a competitor failed to get the...

STC Biologics receives US$2.5 million for biosimilar mAb development Biosimilars/News | Posted 26/10/2012

US-based biotechnology company STC Biologics announced on 10 October 2012 that it had entered into a US$2.5 million phase II Small Business Innovation Research (SBIR) contract with the National Can...

EMA report shows generics applications down but biosimilars up Reports | Posted 19/10/2012

EMA’s mid-year report for 2012 has shown that the number of generics applications is much lower than the agency has predicted, while for biosimilars it is the opposite.

Samsung halts biosimilar rituximab development Biosimilars/News | Posted 19/10/2012

South Korean electronics giant Samsung has halted clinical development for the biosimilar version (SAIT101) of Roche’s Rituxan/MabThera (rituximab).